Market Competition Linked to Change in Generic Drug Prices

Share this content:
Market Competition Linked to Change in Generic Drug Prices
Market Competition Linked to Change in Generic Drug Prices

THURSDAY, July 6, 2017 (HealthDay News) -- Market competition levels are associated with changes in the price of generic drugs, according to a study published online July 4 in the Annals of Internal Medicine.

Chintan V. Dave, Pharm.D., from the University of Florida in Gainesville, and colleagues conducted a retrospective study involving prescription claims for commercial health plans from 2008 to 2013. They calculated the Herfindahl-Hirschman Index (HHI) by summing the squares of individual manufacturers' market shares for each six-month period, with higher values indicating a less competitive market. In each period, the authors estimated the average drug prices for generic drugs. The HHI value estimated in the first half of 2008 was modeled as a fixed covariate.

The researchers identified a cohort of 1,120 generic drugs from 1.08 billion prescription claims. Price changes of −31.7, −11.8, 20.1, and 47.4 percent were seen for drugs with quadropoly (HHI value of 2,500), duopoly (HHI value of 5,000), near-monopoly (HHI value of 8,000), and monopoly (HHI value of 10,000) levels of baseline competition, respectively, over the study period.

"Market competition levels were associated with a change in generic drug prices," the authors write. "Such measurements may be helpful in identifying older prescription drugs at higher risk for price change in the future."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths